Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Latest Financial Results
FY 2025
Fiscal Year Ended Dec 31, 2025
Latest 10-K
Financials
View the latest financials